Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 2
2000 2
2001 2
2002 6
2003 4
2004 6
2005 15
2006 11
2007 5
2008 10
2009 7
2010 7
2011 12
2012 9
2013 15
2014 12
2015 8
2016 9
2017 3
2018 9
2019 12
2020 9
2021 14
2022 25
2023 24
2024 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Results by year

Filters applied: . Clear all
Page 1
T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection.
Musvosvi M, Huang H, Wang C, Xia Q, Rozot V, Krishnan A, Acs P, Cheruku A, Obermoser G, Leslie A, Behar SM, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Walzl G, Hatherill M, Davis MM, Scriba TJ; Adolescent Cohort Study team; GC6-74 Consortium. Musvosvi M, et al. Nat Med. 2023 Jan;29(1):258-269. doi: 10.1038/s41591-022-02110-9. Epub 2023 Jan 5. Nat Med. 2023. PMID: 36604540 Free PMC article.
Profiling the SARS-CoV-2-specific T-cell response.
Geers D, Gommers L, Tan NH, Bogers S, van Baarle D, Grifoni A, Sette A, Boerma A, Visscher F, Richard M, Funk M, Zaeck LM, van der Kuy PHM, Haagmans BL, Koopmans MP, GeurtsvanKessel CH, de Vries RD. Geers D, et al. Among authors: van baarle d. Lancet Infect Dis. 2024 Aug;24(8):e477-e478. doi: 10.1016/S1473-3099(24)00377-3. Epub 2024 Jun 20. Lancet Infect Dis. 2024. PMID: 38909615 No abstract available.
Effect of DMARDs on the immunogenicity of vaccines.
van Sleen Y, van der Geest KSM, Huckriede ALW, van Baarle D, Brouwer E. van Sleen Y, et al. Among authors: van baarle d. Nat Rev Rheumatol. 2023 Sep;19(9):560-575. doi: 10.1038/s41584-023-00992-8. Epub 2023 Jul 12. Nat Rev Rheumatol. 2023. PMID: 37438402 Review.
Frailty is related to serum inflammageing markers: results from the VITAL study.
van Sleen Y, Shetty SA, van der Heiden M, Venema MCA, Gutiérrez-Melo N, Toonen EJM, van Beek J, Buisman AM, van Baarle D, Sauce D. van Sleen Y, et al. Among authors: van baarle d. Immun Ageing. 2023 Nov 27;20(1):68. doi: 10.1186/s12979-023-00391-3. Immun Ageing. 2023. PMID: 38012652 Free PMC article.
The hallmarks of CMV-specific CD8 T-cell differentiation.
van den Berg SPH, Pardieck IN, Lanfermeijer J, Sauce D, Klenerman P, van Baarle D, Arens R. van den Berg SPH, et al. Among authors: van baarle d. Med Microbiol Immunol. 2019 Aug;208(3-4):365-373. doi: 10.1007/s00430-019-00608-7. Epub 2019 Apr 13. Med Microbiol Immunol. 2019. PMID: 30989333 Free PMC article. Review.
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM, Tan NH, Rietdijk WJR, Geers D, Sablerolles RSG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Rugebregt S, Goorhuis A, Postma DF, Visser LG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, Haagmans BL, van Baarle D, Koopmans MPG; SWITCH-ON Research Group; van der Kuy PHM, GeurtsvanKessel CH, de Vries RD. Zaeck LM, et al. Among authors: van baarle d. Nat Commun. 2024 May 18;15(1):4224. doi: 10.1038/s41467-024-48414-x. Nat Commun. 2024. PMID: 38762522 Free PMC article. Clinical Trial.
Vaccines to Protect Older Adults against Pneumococcal Disease.
van de Garde MDB, Knol MJ, Rots NY, van Baarle D, van Els CACM. van de Garde MDB, et al. Among authors: van baarle d. Interdiscip Top Gerontol Geriatr. 2020;43:113-130. doi: 10.1159/000504490. Epub 2020 Apr 9. Interdiscip Top Gerontol Geriatr. 2020. PMID: 32294656 Review.
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH Research Group. Sablerolles RSG, et al. Among authors: van baarle d. N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045226 Free PMC article. Clinical Trial.
231 results